APA (7th ed.) Citation

Dariusz Madajczak, Thierry Daboval, Ryszard Lauterbach, Beata Łoniewska, Witold Błaż, Tomasz Szczapa, . . . the REFSAL Study Group. (2023). Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial). Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Dariusz Madajczak, et al. Protocol for a Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Trial of the Inhaled β2-adrenergic Receptor Agonist Salbutamol for Transient Tachypnea of the Newborn (the REFSAL Trial). Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Dariusz Madajczak, et al. Protocol for a Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Trial of the Inhaled β2-adrenergic Receptor Agonist Salbutamol for Transient Tachypnea of the Newborn (the REFSAL Trial). Frontiers Media S.A., 2023.